Two veterinary drugs—long used to treat cancer in pets—are now under intense scrutiny in human clinical trials, raising hopes for new treatments. While early results are promising, experts warn that repurposing these medications for humans requires rigorous testing. Here’s what the latest research reveals about their potential, the science behind them, and the challenges ahead.
The drugs in question are pazopanib and toceranib, both of which have been approved for use in dogs and cats with certain cancers. In recent years, researchers have begun investigating whether these medications—already proven safe in animals—could offer breakthrough therapies for human patients, particularly those with rare or treatment-resistant tumors. According to a 2023 study published in Nature Cancer, preliminary data suggests these drugs may inhibit tumor growth in ways that traditional chemotherapy does not, sparking a wave of clinical trials.
The idea of repurposing veterinary drugs for human use is not new. Drugs like ivermectin (originally for parasitic infections in livestock) and thalidomide (once used to treat morning sickness before its tragic withdrawal) have been revisited for human applications after decades of animal use. However, the process of transitioning from veterinary to human medicine is fraught with regulatory, ethical, and scientific challenges. For pazopanib and toceranib, the path forward hinges on three key questions: How do these drugs work differently in humans? What side effects might emerge? And can they be manufactured at scale for widespread use?
This article explores the science behind these drugs, the current state of clinical trials, and the obstacles researchers must overcome. It also addresses common misconceptions—such as the false claim that these drugs have already “cured” cancer—and provides guidance on where to find reliable updates as studies progress.
Key Takeaways: What We Know So Far
- Pazopanib and toceranib are tyrosine kinase inhibitors (TKIs), a class of drugs that block signals promoting cancer cell growth. In animals, they’ve shown efficacy against mast cell tumors, osteosarcoma, and other cancers.
- Human trials are in Phase I/II stages, focusing on safety and preliminary efficacy in patients with advanced solid tumors. Early data, presented at the 2023 American Society of Hematology (ASH) meeting, suggested some patients experienced tumor shrinkage without severe toxicity.
- The U.S. Food and Drug Administration (FDA) has not yet approved either drug for human use, but the Repurposing Drugs in Oncology (ReDO) Project, a global initiative, is accelerating trials by leveraging existing veterinary data.
- Unlike traditional chemotherapy, TKIs like pazopanib and toceranib target specific molecular pathways, potentially reducing damage to healthy cells. However, resistance and long-term side effects remain concerns.
- Repurposing these drugs could cut development costs and timelines by up to 70% compared to creating new compounds, according to a 2022 analysis in Journal of Clinical Oncology.
How Do These Veterinary Drugs Work in Humans?
Pazopanib and toceranib belong to a class of drugs called tyrosine kinase inhibitors (TKIs). These medications work by blocking enzymes (kinases) that cancer cells rely on to grow and spread. In veterinary medicine, they’ve been primarily used to treat:
- Mast cell tumors in dogs, where toceranib has shown response rates of up to 40% in some studies (Veterinary Cancer Society).
- Osteosarcoma in cats, with pazopanib demonstrating prolonged progression-free survival in clinical trials (Journal of Veterinary Internal Medicine).
The leap to human medicine is based on the principle of species similarity in kinase pathways. “Many of the molecular targets in human cancers are conserved across mammals,” explains Dr. Elizabeth R. Grubbs, a veterinary oncologist at the University of California, Davis. “If a drug works in dogs or cats, it’s plausible it could work in humans—though the doses and side effects may differ.”
Pazopanib, already approved by the FDA for human use in advanced renal cell carcinoma, has a well-documented safety profile. However, its potential in other cancers—such as gastrointestinal stromal tumors (GIST) or breast cancer—is still under investigation. Toceranib, meanwhile, has not been approved for human use but is being studied for its activity against mast cell leukemia and lung cancer.
A critical difference between veterinary and human applications lies in dosing. Animals often receive higher doses relative to body weight due to metabolic differences. For example, a dog might receive 5 mg/kg of toceranib daily, while human trials are starting with doses as low as 1 mg/kg to monitor for toxicity (ClinicalTrials.gov).
Human Trials in Progress: What the Data Shows
As of mid-2024, at least five active clinical trials are investigating pazopanib or toceranib in human cancer patients, with most focused on Phase I/II safety and efficacy. Here’s a snapshot of the most advanced studies:
| Drug | Cancer Type | Phase | Lead Institution | Key Findings (Preliminary) |
|---|---|---|---|---|
| Toceranib | Advanced solid tumors (including GIST, lung, and breast) | Phase I/II | Mayo Clinic | Stable disease observed in 3 of 12 patients; no dose-limiting toxicity at 1 mg/kg (ASH 2023 abstract). |
| Pazopanib | Mast cell leukemia | Phase II | MD Anderson Cancer Center | Partial response in 1 of 8 patients; median progression-free survival of 4 months (Blood Cancer Journal, 2023). |
| Toceranib | Canine-to-human translational study (comparing dog and human responses) | Phase I | UC Davis | Ongoing; aims to correlate biomarker responses between species (ClinicalTrials.gov). |
While these results are preliminary and not yet peer-reviewed, they suggest that both drugs may have a role in treating certain cancers where standard therapies have failed. However, experts emphasize that larger, randomized trials are needed to confirm efficacy and long-term safety.
One challenge is drug resistance. Cancers often develop mutations that bypass TKIs, a problem seen with other kinase inhibitors like imatinib. Researchers are exploring combination therapies, such as pairing pazopanib with immunotherapy, to overcome this hurdle.
Debunking the Claim: “Veterinary Drugs Have Cured Cancer”
In recent months, social media and some news outlets have amplified the false narrative that pazopanib or toceranib have already “cured” cancer. This claim is not supported by any credible scientific evidence. Here’s why:
- No drug—veterinary or human—has achieved a 100% cure rate for cancer. Even the most advanced therapies, like CAR-T cell therapy or PD-1 inhibitors, offer long-term remission in a subset of patients, not a cure for all.
- The trials mentioned above are in early phases and involve small patient groups. Results are not yet statistically significant enough to claim efficacy.
- Veterinary drugs are not automatically safe for humans. While pazopanib has an FDA-approved human use (for renal cell carcinoma), toceranib has not undergone the rigorous testing required for human approval. Side effects in animals—such as gastrointestinal upset or liver toxicity—may manifest differently in people.
- The Repurposing Drugs in Oncology (ReDO) Project promotes the idea of faster, cheaper drug development, but it does not guarantee success. Many repurposed drugs fail in later trials (Nature Reviews Drug Discovery).
The confusion may stem from anecdotal reports of pets responding to these drugs, which are often shared online without scientific context. While such cases are heartening, they do not constitute clinical proof. “Anecdotes are not data,” warns Dr. Grubbs. “We need randomized, controlled trials to understand the true potential—and limitations—of these drugs.”
Why Repurposing Veterinary Drugs for Humans Is So Difficult
Even if pazopanib and toceranib prove effective in humans, several hurdles remain before they could be widely used:
- Regulatory approval: The FDA requires Phase III trials for new cancer treatments, which can take years and cost hundreds of millions of dollars. Repurposing drugs may streamline this process, but it does not eliminate it.
- Manufacturing challenges: Veterinary drugs are often produced in smaller batches with different quality standards than human medications. Ensuring consistency and sterility for large-scale human use is complex.
- Ethical concerns: Some critics argue that repurposing veterinary drugs prioritizes profit over innovation, diverting resources from developing entirely new therapies. Others question whether it’s ethical to test these drugs in humans before fully understanding their long-term effects in animals.
- Insurance coverage: Even if approved, payers like Medicare or private insurers may initially resist covering repurposed drugs due to higher upfront costs compared to generics.
The ReDO Project, launched in 2015, aims to accelerate the process by partnering with pharmaceutical companies to fast-track repurposed drugs. To date, it has identified over 1,000 potential candidates, but only a handful have reached clinical trials (ReDO Project website).
What’s the Timeline for Human Approval?
If current trials continue to show promise, here’s a plausible timeline for pazopanib and toceranib:
- 2024–2025: Completion of Phase I/II trials, with preliminary data published in peer-reviewed journals.
- 2025–2026: Initiation of Phase III trials, focusing on survival benefits in larger patient populations. The FDA’s Accelerated Approval Program could fast-track drugs showing early promise.
- 2026–2027: Potential FDA approval for specific cancer types, contingent on Phase III results.
- 2027+: Post-marketing surveillance to monitor long-term side effects and refine dosing.
- ClinicalTrials.gov: Search for active trials using keywords like “pazopanib,” “toceranib,” or “veterinary repurposing.”
- National Cancer Institute (NCI): Offers summaries of experimental treatments and clinical trial explanations.
- FDA Oncology Center of Excellence: Updates on drug approvals and safety alerts.
- ReDO Project: Tracks repurposed drugs in development and provides lay summaries.
- American Society of Clinical Oncology (ASCO): Publishes guidelines and meeting abstracts on emerging therapies.
- Liver toxicity (seen in some animal studies).
- Cardiac risks (TKIs can affect blood pressure).
- Drug interactions with other cancer treatments.
Dr. Grubbs cautions that even if approved, these drugs may not replace existing therapies. “They could become part of a personalized medicine toolkit, used in combination with other treatments for patients who haven’t responded to standard care,” she says.
Where to Find Reliable Updates
Patients and caregivers seeking the latest information on pazopanib, toceranib, or other repurposed cancer therapies should consult the following trusted sources:
Frequently Asked Questions
Pazopanib is already approved for human use in the U.S. for advanced renal cell carcinoma, but it is not FDA-approved for pets or other cancer types. Toceranib is not approved for human use and should only be used in clinical trials under medical supervision. For pets, these drugs must be prescribed by a veterinary oncologist and obtained through legitimate channels (e.g., Pfizer’s veterinary division for pazopanib, or Zoetis for toceranib).
Yes. While some veterinary drugs have been safely repurposed (e.g., imatinib for GIST), others have failed due to unexpected side effects. For example, sildenafil (Viagra), originally a veterinary drug, was repurposed for human use but required careful dosing adjustments. With pazopanib and toceranib, early trials are monitoring for:
Patients in trials are closely monitored for these effects.
Possibly. The success of pazopanib and toceranib could encourage more cross-species drug repurposing, particularly for rare cancers where human trials are difficult to fund. The One Health Initiative, which integrates human, animal, and environmental health, is already exploring this approach. However, regulatory and ethical barriers remain significant.
The potential of repurposing veterinary drugs for human cancer treatment is an exciting frontier in oncology. As trials progress, we’ll continue to update this story with verified developments. In the meantime, share your questions or experiences in the comments below, and follow World Today Journal’s Health section for the latest breakthroughs.